Advanced Medical Solutions enters takeover talks with TA Associates

Advanced Medical Solutions ( (GB:AMS) ) has issued an announcement.

Advanced Medical Solutions Group has confirmed it is in talks with private equity firm TA Associates over a possible takeover of the entire issued and to be issued share capital of the company. The disclosure follows recent press speculation and formally places AMS in an offer period under the UK Takeover Code, increasing regulatory scrutiny of dealings in its shares.

TA Associates has until 5 p.m. London time on 16 May 2026 to either announce a firm intention to make an offer or walk away, a deadline that may be extended with Takeover Panel consent. The situation introduces strategic uncertainty for shareholders but underscores the attraction of AMS’s specialist surgical and wound care portfolio to financial buyers, with the board promising further updates when appropriate.

The most recent analyst rating on (GB:AMS) stock is a Hold with a £260.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Spark’s Take on AMS Stock

According to Spark, TipRanks’ AI Analyst, AMS is a Neutral.

The score is mainly driven by mixed financial performance: improving 2025 revenue growth and cash generation, but materially weaker margins/returns versus prior peaks and higher leverage. Technical indicators point to soft momentum with the price below key moving averages. Valuation further pressures the score due to a high P/E, with only modest support from the dividend yield.

To see Spark’s full report on AMS stock, click here.

More about Advanced Medical Solutions

Advanced Medical Solutions Group is a global developer and manufacturer of tissue-healing technologies for surgical and wound care markets. The company’s portfolio spans tissue adhesives, sutures, haemostats, internal fixation devices, sealants and wound dressings, marketed under brands such as LiquiBand, RESORBA, ActivHeal and Peters Surgical, and sold worldwide through partners and direct sales teams.

AMS has expanded its surgical biomaterials and woundcare capabilities through seven acquisitions since 2019, including Sealantis, Biomatlante, Raleigh, AFS Medical, Connexicon, Syntacoll and Peters Surgical. With manufacturing sites across Europe and Asia, multiple R&D hubs and more than 1,600 employees, it targets hospitals and healthcare systems seeking improved patient outcomes and cost-effective therapies.

Average Trading Volume: 1,007,443

Technical Sentiment Signal: Strong Buy

Current Market Cap: £469.6M

See more insights into AMS stock on TipRanks’ Stock Analysis page.